jittawit.21
Antibiotic developer Paratek Pharmaceuticals (NASDAQ:PRTK) has agreed to be taken private by Gurnet Point Capital and Novo Holdings, the investment arm of the Novo Nordisk Foundation, for up to approximately $462M.
Under the deal, the investment firms will pay $2.15 per share in cash upfront. Shareholders will also receive contingent value rights worth $0.85 per share payable if Paratek’s lead drug, an antibiotic called Nuzyra, achieves US net sales of $320M in any calendar year before 2027, according to a statement.
The companies said the upfront cash payment represents a 41% premium over Paratek’s closing price on May 31, the last session before market speculation emerged about a possible takeover deal.
The acquisition is expected to close in Q3, after which Paratek’s shares will cease trading on Nasdaq.
More on Paratek:
Paratek Pharmaceuticals jumps amid report about takeover interest
Paratek a new buy at Jefferies on growing antibiotics business
Paratek Pharmaceuticals up 20% on takeout speculation – report
